BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 29262669)

  • 21. Current treatment options in prolymphocytic leukemia.
    Robak T; Robak P
    Med Sci Monit; 2007 Apr; 13(4):RA69-80. PubMed ID: 17392661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways.
    Braun T; Glass M; Wahnschaffe L; Otte M; Mayer P; Franitza M; Altmüller J; Hallek M; Hüttelmaier S; Schrader A; Herling M
    Haematologica; 2022 Jan; 107(1):187-200. PubMed ID: 33543866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).
    Jain P; Aoki E; Keating M; Wierda WG; O'Brien S; Gonzalez GN; Ferrajoli A; Jain N; Thompson PA; Jabbour E; Kanagal-Shamanna R; Pierce S; Alousi A; Hosing C; Khouri I; Estrov Z; Cortes J; Kantarjian H; Ravandi F; Kadia TM
    Ann Oncol; 2017 Jul; 28(7):1554-1559. PubMed ID: 28379307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Comprehensive Update on Molecular and Cytogenetic Abnormalities in T-cell Prolymphocytic Leukemia (T-pll).
    Delgado P; Starshak P; Rao N; Tirado CA
    J Assoc Genet Technol; 2012; 38(4):193-8. PubMed ID: 23183331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker.
    Stengel A; Kern W; Zenger M; Perglerová K; Schnittger S; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2016 Jan; 55(1):82-94. PubMed ID: 26493028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia.
    Matutes E; Brito-Babapulle V; Swansbury J; Ellis J; Morilla R; Dearden C; Sempere A; Catovsky D
    Blood; 1991 Dec; 78(12):3269-74. PubMed ID: 1742486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [T-cell prolymphocytic leukemia complicated by diffuse large B-cell lymphoma of the stomach].
    Miyata A; Yoshino T; Kojima K; Fujii S; Kikuchi T
    Rinsho Ketsueki; 2001 Jan; 42(1):47-50. PubMed ID: 11235134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances and Perspectives in the Treatment of T-PLL.
    Braun T; von Jan J; Wahnschaffe L; Herling M
    Curr Hematol Malig Rep; 2020 Apr; 15(2):113-124. PubMed ID: 32034661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia.
    Paul RN; Alizadeh L; Ajayi OI; Karpurapu H; Ganesan C; Taddesse-Heath L; Aggarwal A
    Acta Haematol; 2012; 127(4):235-43. PubMed ID: 22517037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How I treat prolymphocytic leukemia.
    Dearden C
    Blood; 2012 Jul; 120(3):538-51. PubMed ID: 22649104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia.
    Patil P; Cieslak A; Bernhart SH; Toprak UH; Wagener R; López C; Wiehle L; Bens S; Altmüller J; Franitza M; Scholz I; Jayne S; Ahearne MJ; Scheffold A; Jebaraj BMC; Schneider C; Costa D; Braun T; Schrader A; Campo E; Dyer MJS; Nürnberg P; Dürig J; Johansson P; Böttcher S; Schlesner M; Herling M; Stilgenbauer S; Macintyre E; Siebert R
    Genes Chromosomes Cancer; 2020 Apr; 59(4):261-267. PubMed ID: 31677197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy.
    Hu Z; Li S; Medeiros LJ; Sun T
    Hum Pathol; 2017 Jul; 65():175-179. PubMed ID: 28232160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia.
    Johansson P; Klein-Hitpass L; Röth A; Möllmann M; Reinhardt HC; Dührsen U; Dürig J
    Eur J Haematol; 2020 Dec; 105(6):786-796. PubMed ID: 32875608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent Hodgkin's disease (mixed cellularity type) and T-cell chronic lymphocytic leukemia/prolymphocytic leukemia.
    Miyata A; Kojima K; Yoshino T; Fujii S; Shinagawa K; Ichimura K
    Int J Hematol; 2001 Feb; 73(2):230-5. PubMed ID: 11372737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
    Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
    Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of karyotyping,
    Sun Y; Tang G; Hu Z; Thakral B; Miranda RN; Medeiros LJ; Wang SA
    J Clin Pathol; 2018 Apr; 71(4):309-315. PubMed ID: 28821581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenotypical heterogeneity of CD4+CD8+ double-positive chronic T lymphoid leukemia.
    Mizuki M; Tagawa S; Machii T; Shibano M; Tatsumi E; Tsubaki K; Tako H; Yokohama A; Satou S; Nojima J; Hirota T; Kitani T
    Leukemia; 1998 Apr; 12(4):499-504. PubMed ID: 9557607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab].
    Fløisand Y; Brinch L; Gedde-Dahl T; Tjønnfjord GE
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):768-70. PubMed ID: 15039804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.
    Damlaj M; Sulai NH; Oliveira JL; Ketterling RP; Hashmi S; Witzig T; Nowakowski G; Call TG; Shanafelt TD; Ding W; Hogan WJ; Litzow MR; Patnaik MM
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):699-704. PubMed ID: 26422251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.
    López C; Bergmann AK; Paul U; Murga Penas EM; Nagel I; Betts MJ; Johansson P; Ritgen M; Baumann T; Aymerich M; Jayne S; Russell RB; Campo E; Dyer MJ; Dürig J; Siebert R
    Br J Haematol; 2016 Apr; 173(2):265-73. PubMed ID: 26917488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.